KU-0063794 was originally developed as part of the Kudos Biochemical experimental program, Pfizer in 2009 bought Kudos Biochemicals for its pipeline portfolio; KU has not been clinically developed since then. KU-0063794 is a highly specific inhibitor against mTOR 1 and 2 with IC50 of approximately 3-100 nM for mTOR1 and 2 depending on which cell line is tested. KU-0063794 dis played no activity at PI 3-kinase or 76 other kinases tested, it Inhibits activation and hydrophobic motif phosphorylation of Akt, S6K and SGK, but not RSK, in addition, this compound suppresses cell growth and induces G1 cell cycle arrest in vitro. Ku-0063794 was effective in decreasing the viability and growth of renal cell carcinoma, Caki-1 and 786-O, in vitro by inducing cell cycle arrest and autophagy, but not apoptosis. In addition, experiments in vitro showed that Ku-0063794 possessed therapeutic potential for the treatment of keloid disease and acute lymphoblastic leukemia.

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. Tranilast is used for the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.